Prostate cancer, or prostatic carcinoma, occurs in a small walnut-shaped gland in males that is responsible for producing the seminal fluid which nourishes and transports sperm—the prostate. Symptoms of prostate cancer often include increased frequency and difficulty/pain urinating, decreased control over the stream of urine, blood in semen or urine, pelvic area discomfort, and erectile dysfunction.
In the United States, this cancer kills over 34,000 men each a year and is a subtype, or speciality, inside the general study of oncology and carcinogenesis, cancer cell biology, cancer diagnosis, and cancer therapy. Primary care physicians, internists, and urologists are able to diagnose this disease, however, prostate cancer is treated by oncologists.
Special Collection: Prostate Cancer
The Oncotarget Journal publishes open-access and peer-reviewed literature on research studies and perspectives, clinical studies, reviews, case reports, and meta-analyses about a variety of different topics pertaining to cancer. Prostate cancer continues to be an area of interest for researchers, therefore, the Special Collection on Prostate Cancer was created by Oncotarget as a resource for scientists and researchers to discover new biomarkers, mechanisms, and therapies to treat this cancer.
All content submitted for publication in Oncotarget has been reviewed by a diligent board of academic editors and world-renowned scientists and researchers. Some of the research available in Oncotarget’s Special Collection on Prostate Cancer includes studies on bacterial cancer therapy used in mouse-modeled prostate cancer, groundbreaking findings of exponentially growing and symmetrically dividing prostate cancer cells, novel microRNA biomarkers, and retrospective studies, such as one from Russian researchers on melatonin’s anticancer effects in males with prostate cancer.
Within this collection, authors from around the world have published literature on prostate cancer. Some countries of origin include: the United States, Canada, Chile, Russia, Germany, Sweden, Switzerland, Norway, China, and Japan—to name a few. In addition to being situated around the globe, authors of literature within Oncotarget’s Special Collection on Prostate Cancer submit their work from leading-edge research facilities and clinical and academic institutions. A handful of these notable institutions include, but are not limited to, the Mayo Clinic, Roswell Park Cancer Institute, Harvard Medical School, Yale University, Johns Hopkins University, National Science Foundation, and Columbia University Irving Medical Center.
The majority of papers published in this collection are high-scoring Dimensions and Altmetric rated literature, including a research paper authored by researchers from the United States and the United Kingdom, titled: “The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells.”
This Special Collection by Oncotarget is meant to be a tool researchers and science readers alike may use to learn more about the current landscape of prostate cancer. The creators of these collections are hopeful that this resource may help researchers discover new biomarkers, mechanisms, and therapies that improve our collective quality of life and lead to enhanced treatments for cancer and other diseases.
Read the Special Collection on Prostate Cancer at Oncotarget.com.
—
Oncotarget is a unique platform designed to house scientific studies in a journal format that is available for anyone to read—without a paywall making access more difficult. This means information that has the potential to benefit our societies from the inside out can be shared with friends, neighbors, colleagues, and other researchers, far and wide.
For media inquiries, please contact media@impactjournals.com.